Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EBOS Group Limited ( (AU:EBO) ) just unveiled an update.
EBOS Group Limited announced a change in the director’s interest, specifically involving Matthew Musico, the CEO of EBOS Medical Technology. On September 4, 2025, 15,828 performance rights held by Mr. Musico lapsed, reducing his holdings to 17,859 performance rights. This change reflects the lapse of performance rights in accordance with their terms of issue, which could impact the director’s stake in the company but does not indicate any immediate operational or strategic shifts for EBOS Group.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$33.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited operates in the medical technology sector, providing products and services related to healthcare and pharmaceuticals. The company focuses on delivering innovative solutions to enhance medical practices and patient care.
Average Trading Volume: 106,249
Technical Sentiment Signal: Sell
Current Market Cap: A$5.64B
See more data about EBO stock on TipRanks’ Stock Analysis page.